July 9, 2018 04:02 AM EDT
R&D
Pharma

Fo­cused on re­build­ing the pipeline, Ax­o­van­t's new crew as­sem­bles an­oth­er pre­clin­i­cal gene ther­a­py deal

John Carroll

Editor & Founder

Just a few weeks af­ter Vivek Ra­maswamy’s Ax­o­vant $AX­ON got a big boost out of its li­cens­ing pact with Ox­ford Bio­Med­ica for what is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

New Flag­ship start­up aims to trail­blaze ‘AI sci­ence fac­to­ries’

Beam shares promis­ing first clin­i­cal da­ta on gene edit­ing treat­ment for a lung and liv­er dis­ease 

Ex­clu­sive: FDA blocks drug and de­vice re­view­ers from tak­ing HH­S' buy­out of­fer

Emer­gent sells once-trou­bled man­u­fac­tur­ing site to In­di­an CD­MO

Sun Phar­ma to ac­quire Check­point Ther­a­peu­tics and its an­ti-PD-L1 an­ti­body

sponsored

Obe­si­ty drug de­vel­op­ment—still room to grow

A service from the Financial Times